We are Sorry, This Page doesn't Exist
AstraZeneca slips 1% after disappointing cancer-drug trial
This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more information about this breaking news......»»
Merck"s stock surges after positive Keytruda trial results
Shares of Merck & Co. Inc. surged 2.6% in premarket trade Monday, after the drug maker said its cancer treatment Keytruda met the primary endpoint of a phase 3 trial evaluating the Keytr.....»»
Merck"s Keytruda meets main goal in pivotal lung cancer trial
(Reuters) - Merck & Co said on Monday a late-stage trial of its blockbuster cancer drug Keytruda met the main goal in helping previously untreated lung cancer patients live longer, sending its shares up 2.6 percent in premarket trade......»»
Loxo Oncology shares surge nearly 20% on preview of cancer drug trial data
This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more information about this breaking news......»»
Loxo Oncology shares surge 21% on preview of cancer drug trial data
Loxo Oncology Inc. shares surged 20.8% in heavy Thursday mo.....»»
Loxo shares surge 11% on early-stage cancer drug trial
This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more information about this breaking news......»»
Loxo shares surge 8% on early-stage cancer drug trial
Loxo Oncology Inc. shares surged 8.3% in morning trade Monday after the company released positive result.....»»
Nektar"s 39% Drop: A New Record for a Volatile Stock
Shares slide on weak cancer-drug trial data......»»
UPDATE: Merrimack Pharma shares slide 34% after trial of pancreatic cancer treatment fails to meet main goals
Merrimack Pharmaceuticals Inc. said Monday a midstage trial of a treatment for pancreatic cancer failed to meet its main goals. The clinical.....»»
Sophiris Bio shares plummet 46% on news of patient death in trial for prostate cancer drug
Sophiris Bio Inc. shares plummeted nearly 46% in prem.....»»
Aquinox Pharma shares slide 73% premarket after cystitis drug trial fails to meet main goal
Aquinox Pharmaceuticals Inc. shares slid 73% in premarket trade Wednesday, after the Canadian-based biotech said a trial of a treatment for cystitis and severe bladder.....»»
Hitting cancer early: AstraZeneca"s bid to outmaneuver rivals
LONDON (Reuters) - AstraZeneca suffered its biggest daily share price drop a year ago after a key cancer drug trial failed amid feverish speculation the chief executive might quit......»»
Advaxis shares rise 68% after FDA lifts clinical hold on its drug trial
Shares of the biotech company Advaxis Inc. surged 68% in premarket trade on Friday after the Food and Drug Administration lifted a clinical hold on the company's phase 1/2 study for a cancer drug combination. The clinical hol.....»»
Cellectar Shares Climb After Strong Trial Response For Rare Blood Cancer Drug
Cellectar Biosciences Inc (NASDAQ: CLRB) shares are pushing northward on over five times their average volume after the company reported positive results from an ongoing midstage trial. read more.....»»
Mersana Therapeutics shares plummet 40% after patient death in cancer trial
Mersana Therapeutics Inc. said early Thursday that, after the company reported a patient death in its cancer drug trial, the Food and Drug Administrat.....»»
Celgene shares lift on positive results for cancer drug trial
Celgene Corp. shares rose 1.6% in Tuesday premarket trade after the company reported positive results from a phase 3 cancer trial after-hours the previous day. The trial evaluated Celgene's chemotherapy drug Revlimid .....»»
Merrimack Pharmaceuticals" stock plummets toward record low after cancer drug trial terminated
Shares of Merrimack Pharmaceuticals Inc. plummeted 35% toward a record low in .....»»
Mirati Therapeutics stock drops 30% premarket after cancer trial results
Mirati Therapeutics Inc. shares dropped 30% in Monday premarket trade after the company presented results from a phase 2 trial in which its cancer drug sitravatinib was combined with Bristol-Myers Squibb Co.'s cancer drug Opdivo . The trial enrolled p.....»»
Immunomedics Shares Crash As Breast Cancer Drug Fails To Obtain Regulatory Nod
Immunomedics, Inc. (NASDAQ: IMMU) shares were plunging Friday following an adverse regulatory development. read more.....»»
Immunogen"s stock loses nearly half its value after trial of cancer treatment fails to meet primary endpoint
Shares of Immunogen Inc. plummeted 48% toward a two-year low in premarket trade Friday, after the company said a phase 3 trial of its ovarian cancer treatment, m.....»»